Patrick Michael Round

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.

Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The private company is based in Newmarket, UK. Xention was founded in 2002.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

ario pharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of respiratory indications. The company was founded by John Ford and Patrick M. Round in 2010 and is headquartered in Great Shelford, the United Kingdom.

Celltech R&D, Inc. provides research and development services for pharmaceutical products. The private company is based in Bothell, WA.

Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom.